BCYC BICYCLE THERAPEUTICS PLC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1761612 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY194.7%
TTM net income YoY43.4%
TTM EPS YoY43.9%
Revenue 3-yr CAGR49.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-189.4%
Net margin-169.8%
FCF margin-211.9%
EBITDA margin-183.8%
Returns
ROE-25.2%
ROA-21.3%
ROIC (approx.)-4,542.9%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio12.09x
Interest coverage-815.60x
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio5.0%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $72.59M | $35.27M |
| R&D expense | $240.28M | $172.97M |
| SG&A expense | $79.37M | $72.18M |
| Operating income | -$247.06M | -$209.87M |
| Interest expense | $206,000 | $1.73M |
| Pretax income | -$218.81M | -$173.80M |
| Income tax | $152,000 | -$4.76M |
| Net income | -$218.96M | -$169.03M |
| EBITDA | -$240.64M | -$202.70M |
| EPS (basic) | -3.16 | -2.90 |
| EPS (diluted) | -3.16 | -2.90 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 69.28M | 58.21M |
| Balance sheet | ||
| Cash & equivalents | $628.11M | $880.07M |
| Receivables | $0 | $0 |
| Current assets | $682.88M | $928.61M |
| PP&E, net | $6.02M | $9.52M |
| Total assets | $717.60M | $956.87M |
| Current liabilities | $56.98M | $67.23M |
| Total liabilities | $107.62M | $163.81M |
| Shareholders' equity | $609.98M | $793.06M |
| Shares outstanding | 69.37M | 69.06M |
| Cash flow statement | ||
| Operating cash flow | -$249.68M | -$164.72M |
| Capital expenditure | $2.35M | $1.24M |
| Free cash flow | -$252.03M | -$165.96M |
| Investing cash flow | -$2.35M | -$1.24M |
| Financing cash flow | -$131,000 | $519.75M |
| Depreciation & amortization | $6.42M | $7.17M |
| Stock-based compensation | $39.46M | $38.08M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.